â– PHYSIOLOGICAL CORE: The Protein C and S pathway is an endogenous anticoagulant system that regulates the propagation of the coagulation cascade.
â– INTERACTION PATHWAYS:
1. Thrombomodulin Association: Excess thrombin binds to thrombomodulin on healthy endothelial cell membranes.
2. Receptor Complex: The thrombin-thrombomodulin complex activates Protein C (to APC) bound to its endothelial receptor.
3. Cofactor Association: APC associates with its free cofactor Protein S.
4. Inactivation: The APC-Protein S complex proteolytically inactivates the active cofactors VIIIa and Va.
5. Coagulation Halt: Inactivating VIIIa and Va halts the tenase and prothrombinase complexes, preventing excessive thrombin propagation on normal tissue.
â– TOXICOLOGICAL OVERDOSAGE PROTOCOL:
Toxic absorption or cumulative exposure results in receptor saturation, chemical cell damage, or severe secondary target-organ failure. Immediate toxicological profiles dictate serum or urine screens.
â– CLINICAL CASE SUMMARY:
A 45-year-old patient presented with acute clinical deterioration. Aggressive initial stabilization, molecular monitoring, and specialized pathology screening confirmed the classic disease hallmarks.
[HY-BOARD-1039]
🌟 Dynamic Clinical Key:
Factor V Leiden is caused by a genetic mutation (Arg506Gln) in the Factor V gene. This mutation alters the cleavage site for Activated Protein C, rendering Factor Va resistant to inactivation (APC resistance). This is the most common hereditary cause of hypercoagulability (thrombophilia) in Caucasians. Administer physiological antidotes and active elimination therapies (activated charcoal or hemodialysis) without delay. Clinical vigilance during early presentation prevents progression along the severe outcome pathway.